Engitix, a biotech company targeting the extracellular matrix (ECM) to develop therapies for cancer and fibrosis, has closed £18.6m in series A extension funding.
Engitix leverages deep, high-resolution ECM data to identify disease-associated signatures and translate them into therapeutics designed to act precisely within diseased tissue microenvironments.
The investment will be used to continue preclinical development across Engitix’s proprietary ECM-targeted pipeline in solid tumours and fibrosis.
It will also be utilised to further expand and apply the company’s platform built on one of the largest proprietary ECM datasets for these diseases.
“Closing this financing strengthens our ability to translate Engitix’s unique ECM understanding into a growing pipeline of targeted therapeutics,” said Giuseppe Mazza, CEO and co-founder at Engitix.
“Our platform and dataset position us to accelerate preclinical development across oncology and fibrosis programs and build differentiated, ECM-targeted therapeutics with the potential to meaningfully improve patient outcomes.”
The extension funding was provided by Netherton Investments, a fund investing on behalf of Mike Platt, the co-founder and managing director at BlueCrest Capital Management.
“Engitix has developed a compelling strategy at the intersection of data, biology, and drug development,” adds Platt. “I’m pleased to continue supporting Engitix as it advances its programs in fibrosis and solid tumours.”
